Preview

Obstetrics, Gynecology and Reproduction

Advanced search

PATHOGENIC ASPECTS OF INTERACTION BETWEEN THE TUMOR TISSUE AND HEMOSTATIC SYSTEM

https://doi.org/10.17749/2313-7347.2015.10.1.084-098

Full Text:

Abstract

Cancer is a risk factor for thrombotic complications, while activation of the hemostatic system contributes to the growth and metastasis of the tumor tissue. The paper presents the modern ideas of the pathogenetic features of the interaction of the hemostatic system and immune systems in terms of tumor growth. First category of such factors we refer to as "specific tumor-dependent", the second – as "general pathological risk factors", the third – as "therapy-dependent" risk factors. Pathogenesis of interaction "hemostatic system – tumor tissue – immune system" includes factors related to the response to the tumor: inflammation, acute phase reaction, dysproteinemia, focal necrosis, hemodynamic abnormalities, as well as specific factors caused by the tumor cells and tumor-associated macrophages. Namely: procoagulant and fibrinolytic activity of cancer cells and their interaction with platelets, mononuclear macrophages and endothelium, angiogenesis, iatrogenic aspects (chemoherapy, hormone therapy). Tumor cells activate the coagulation cascade or fibrinolysis system, providing conditions for its further spread, stimulation of angiogenesis, increased vascular 
permeability, which in turn promotes metastasis.

About the Authors

A. D. Makatsariya
First Moscow State Medical Sechenov University of the Ministry of Health Russian Federation
Russian Federation

MD, corresponding member of the Russian Academy of Sciences, Professor, Head of the Department of Obstetrics and Gynecology, Faculty of Medical and Preventive, First Moscow State Medical Sechenov University. Address: ul. Trubetskaya, 8, str. 2, Moskva, Russia, 119048. Tel.: +7(495)7885840



A. V. Vorobev
First Moscow State Medical Sechenov University of the Ministry of Health Russian Federation
Russian Federation

PhD, Associate Professor, Department of Obstetrics and Gynecology, Faculty of Medical and Preventive Medicine First Moscow Medical Sechenov University. Address: ul. Zemlyanoy Val, 62, p. 1, Moscow, Russia, 109004. Tel.: +7(495)1999262



A. M. Chabrov
Cancer clinical dispensary №1 Department of Health of Moscow
Russian Federation

MD, PhD., head of gynecological department Clinical Oncological Dispensary №1 Moscow Health Department. Address: ul. Volochaevskaya, 36, Moscow, Russia, 109033. Tel.: +7(495) 3616255



A. A. Savchenko
Cancer clinical dispensary №1 Department of Health of Moscow
Russian Federation

PhD, gynecological department Clinical Oncological Dispensary №1 Moscow Health Department. Address: ul. Volochaevskaya, 36, Moscow, Russia, 109033. Tel.: +7(495)3616255



A. L. Mishchenko
First Moscow State Medical Sechenov University of the Ministry of Health Russian Federation
Russian Federation

MD, research assistance of Scientific Educational Clinical Centre «Clinical Hemostasiology», First Moscow State Medical Sechenov University. Address: ul. Trubetskaya, 8, str. 2, Moskva, Russia, 119048. Tel.: +7(495)7885840



References

1. Blinov D.V., Terent'ev S.S. Neurochemistry / Neirokhimiya. 2013; 30 (3): 179-192.

2. Blinov D.V. Epilepsiya i paroksizmal'nye sostoyaniya / Epilepsy and paroxysmal conditions. 2013; 3: 65-75.

3. Blinov D.V. Epilepsiya i paroksizmal'nye sostoyaniya / Epilepsy and paroxysmal conditions. 2014; 1: 70-84.

4. Blinov D.V. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology 2014; 7 (1): 40-45.

5. Vorobev A.V. Voprosy ginekologii, akusherstva i perinatologii. 2008; 2 (7): 18-25.

6. Makatsariya A.D., Vorob'ev A.V., Bitsadze V.O. Malignancies, thrombophilia, thrombosis. Monograph. [Zlokachestvennye novoobrazovaniya, trombofiliya, trombozy. Monografiya (in Russian)]. Moscow. 2008; 650 s.

7. Tsyb A.F., Sushkevich G.N., Baluda M.V., Vorob'ev A.V., Chabrov A.M. Principles of prevention of thrombotic complications in patients with cancer (solid tumors). Manual for physicians [Printsipy profilaktiki tromboticheskikh oslozhnenii u onkologicheskikh bol'nykh (solidnye obrazovaniya). Posobie dlya vrachei (in Russian)]. Obninsk. 2008; 42 s.

8. Abildgaard U., Lindahl A.K., Sandset P.M. Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood. Haemostasis. 1991; 21: 254-7.

9. Ay C., Vormittag R., Dunkler D. et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2009; 27 (25): 4124-4129.

10. Batsis J.A., Morgenthaler T.I. Trousseau syndrome and the unknown cancer: use of positron emission tomographic imaging in a patient with a paraneoplastic syndrome. Mayo Clin Proc. 2005 Apr; 80 (4): 537-4.

11. Bell W.R., Starksen N.F., Tong S., Porterfield J.K. Trousseau's syndrome. Devastating coagulopathy in the absence of heparin. Am J Med. 1985; 79: 423-30.

12. Bogenrieder T., Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene. 2003; 22: 6524-36.

13. Donati M.B., Falanga A. Patogenetic Mechanisms of Thrombosis in Malignancy. Acta Haematol. 2001; 106: 18-24.

14. Falanga A., Marchetti M., Vignoli A. Pathogenesis of thrombosis in cancer. Thromb and cancer. 2004; 30: 11-23.

15. Gouin-Thibault I., Achkar A., Samama M.M. The thrombophilic state in cancer patients. Acta Haematol. 2001; 106 (1-2): 33-42.

16. Gray E., Mulloy B., Barrowcliffe T.W. Heparin and low-molecularweight heparin. Thromb Haemost. 2008; 99: 807-18.

17. Khorana A.A., Ahrendt S.A., Ryan C.K. et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007; 13 (10): 2870-2875.

18. Khorana A.A., Francis C.W., Culakova E., Kuderer N.M., Lyman G.H. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007; 5 (3): 632-634.

19. Khorana A.A., Francis C.W., Menzies K.E. et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost. 2008; 6 (11): 1983-1985.

20. Khorana A.A. Venous thromboembolism and prognosis in cancer. Thromb Res. 2010; 125 (6): 490-493.

21. Lee A.Y.Y. Screening for occult cancer in patients with idiopathic venous thromboembolism. J Thromb Haemost. 2003; 1: 2273-2274.

22. Ludwig R.J., Alban S., Bistrian R., Boehncke W.H., Kaufmann R., Henschler R., Gille J. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost. 2006; 95: 535-40.

23. Mandala M., Clerici M., Corradino I. et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the ‘SENDO experience’. Ann Oncol. 2012; 23 (6): 1416-1421.

24. Menapace L.A., Peterson D.R., Berry A., Sousou T. and Khorana A.A. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost. 106 (2): 371-378.

25. Monreal M., Davant E. Thrombotic complications of central venous catheters

26. in cancer patients. Acta Haematol. 2001; 106 (1-2): 69-72.

27. Moore R.A., Adel N., Riedel E. et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011; 29 (25): 3466-3473.

28. Prandoni P., Lensing A.W., Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100 (10): 3484-3488.

29. Prandoni P., Falanga A., Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005 Jun; 6 (6): 401-10.

30. Samama M.M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med. 2000; 160: 3415-20.

31. Shaker A. Mousa. Low-Molecular-Weight Heparin in Thrombosis and Cancer. Seminars in thrombosis and hemostasis. 2004; 30: 25-29.

32. Sørensen H.T., Mellemkjaer L., Olsen J.H., Baron J.A. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000; 343 (25): 1846-1850.

33. von Tempelhoff G.F., Harenberg J., Niemann F. et al. Effect of low molecular weight heparin (certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol. 2000; 16: 815-824.

34. Wun T.C. Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: Synergistic anticoagulant action between LACI and sulfated polysaccharides. Blood. 1992; 79: 430-8.

35. Zach arski Leo R. Malignancy as a solid-phase coagulopathy: implications for the etiology, pathogenesis, and treatment of cancer. Seminars in thrombosis and hemostasis. 2003; 29: 239-46.


For citation:


Makatsariya A.D., Vorobev A.V., Chabrov A.M., Savchenko A.A., Mishchenko A.L. PATHOGENIC ASPECTS OF INTERACTION BETWEEN THE TUMOR TISSUE AND HEMOSTATIC SYSTEM. Obstetrics, Gynecology and Reproduction. 2016;10(1):84-98. (In Russ.) https://doi.org/10.17749/2313-7347.2015.10.1.084-098

Views: 164


ISSN 2313-7347 (Print)
ISSN 2500-3194 (Online)